Sexually transmitted diseases (STDs) are common, and result in immense social and economic costs.
In some countries they have a major demographic impact.
Because many STDs facilitate the transmission of HN, the consequences of STDs are further increasing.
At the same time, this association between STDs and HN provides one of the ways in which drug therapy should be very cost effective.
The perspective taken in this article is a societal one, and broader issues than those directly related to drug costs and benefits are discussed.
However, it is the availability of drugs that has the potential to most quickly and most reliably make a major difference to overall health sector and societal costs as they relate to STDs.
For those STDs for which curative therapy is available (particularly Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and Trichomonas vaginalis) there have been large decreases in prevalence in many parts of the world.
In contrast, those STDs for which curative therapy is not available (particularly HIV, genital herpes and genital human papillomavirus infection) have had stable or increasing prevalence.
For these latter infections, each new case increases the overall prevalence.
Numerous features of STDs make clinical and economic evaluation difficult.
Mots-clés Pascal : Médicament, Article synthèse, Maladie sexuellement transmissible, Epidémiologie, Socioéconomie, Traitement, Chimiothérapie, Essai clinique, Homme, Economie santé, Qualité vie
Mots-clés Pascal anglais : Drug, Review, Sexually transmitted disease, Epidemiology, Socioeconomics, Treatment, Chemotherapy, Clinical trial, Human, Health economy, Quality of life
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0188928
Code Inist : 002B02S06. Création : 09/06/1995.